Predictors of Cancer-Related Fatigue in Women With Breast Cancer Before, During, and After Adjuvant Therapy

Center for Enhancing Quality of Life in Chronic Illness, Indiana University School of Nursing, Indianapolis, Indiana 46202, USA.
Cancer nursing (Impact Factor: 1.97). 03/2008; 31(2):134-44. DOI: 10.1097/01.NCC.0000305704.84164.54
Source: PubMed


The purpose of this longitudinal study was to examine potential predictors of cancer-related fatigue (CRF) before, during, and after adjuvant therapy in women with breast cancer. A convenience sample of 44 women postsurgery (M = 18) aged 38 to 77 years (M = 52) were recruited from a Southern breast clinic. Based on Piper's Integrated Fatigue Model, the women (1) completed questionnaires assessing innate host factors (age, income, and education level), disease and treatment patterns (disease stage, surgery type, and adjuvant therapy), psychological patterns (perceived stress, mood disturbance, and optimism), social patterns (type and satisfaction with social support) and (2) provided a blood sample to examine regulation patterns (morning cortisol levels, interleukin-1 beta, tumor necrosis factor alpha, and natural killer cell activity) before adjuvant therapy. The Piper Fatigue Scale-Revised was completed at all 3 time points. Mood disturbance was the most significant predictor of CRF at all time points. Interleukin-1 beta predicted CRF levels before adjuvant therapy and morning cortisol before adjuvant therapy predicted CRF during and after adjuvant therapy. These findings suggest that interventions to reduce mood disturbances might be effective in decreasing CRF. Further research regarding the physiological mechanisms underlying the relationships between CRF, mood disturbance, interleukin-1 beta, and cortisol is needed.

Download full-text


Available from: Diane M Von Ah, Jul 02, 2014
  • Source
    • "Although there is a significant body of literature evaluating HRQoL in women with breast cancer,[9,10] much of this work has been focused on survivorship,[11-13] women treated in adjuvant settings,[14-16] or in women with recurrent disease[17-19]. HRQoL research with mBC patients has occurred primarily in the clinical trial setting,[20-22] has included multiple cancer types,[23] and has focused on characterizing HRQoL at either a single point in time or at a couple of fixed time points[23,24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This retrospective study evaluated the impact of disease progression and of specific sites of metastasis on patient reported outcomes (PROs) that assess symptom burden and health related quality of life (HRQoL) in women with metastatic breast cancer (mBC). HER-2 negative mBC patients (n = 102) were enrolled from 7 U.S. community oncology practices. Demographic, disease and treatment characteristics were abstracted from electronic medical records and linked to archived Patient Care Monitor (PCM) assessments. The PCM is a self-report measure of symptom burden and HRQoL administered as part of routine care in participating practices. Linear mixed models were used to examine change in PCM scores over time. Mean age was 57 years, with 72% of patients Caucasian, and 25% African American. Median time from mBC diagnosis to first disease progression was 8.8 months. Metastasis to bone (60%), lung (28%) and liver (26%) predominated at initial metastatic diagnosis. Results showed that PCM items assessing fatigue, physical pain and trouble sleeping were sensitive to either general effects of disease progression or to effects associated with specific sites of metastasis. Progression of disease was also associated with modest but significant worsening of General Physical Symptoms, Treatment Side Effects, Acute Distress and Impaired Performance index scores. In addition, there were marked detrimental effects of liver metastasis on Treatment Side Effects, and of brain metastasis on Acute Distress. Disease progression has a detrimental impact on cancer-related symptoms. Delaying disease progression may have a positive impact on patients' HRQoL.
    Health and Quality of Life Outcomes 06/2011; 9(24 Supplement):46. DOI:10.1186/1477-7525-9-46 · 2.12 Impact Factor

  • Journal of Professional Nursing 1(3):124. · 0.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A new system enhancement method is proposed for the EIA/TIA-136 system offering both channel operational range extension and improved performance within the current operational range. The research presented investigates the application of the narrowband adaptive multi-rate (NB-AMR) speech codec and the wideband AMR (WB-AMR) codec, both originally designed for the 200 kHz GSM channel, in the TDMA (TIA/EIA-136) 30 kHz system. In particular, we investigate adaptively allocating bits between NB/WB speech coding and error control within the limited channel bandwidth. Four modes out of seventeen have been carefully chosen for the new TDMA/AMR system. Switching between codec rates as channel conditions change produces range extension below a C/I of 15 dB while also improving performance in the existing operational range above 15 dB. Time slot formats are unchanged so that the method is completely compatible with existing 136 systems.
    Signals, Systems and Computers, 2002. Conference Record of the Thirty-Sixth Asilomar Conference on; 12/2002
Show more